Sigilon Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Sigilon Therapeutics

10/11/2022 14:26

* Sigilon Therapeutics Inc  SGTX.OQ  reported a quarterly
adjusted
loss of 27 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 42 cents per share.
    * Revenue rose 118.4% to $4.25 million from a year ago;
analysts
expected $2.50 million. 
    * Sigilon Therapeutics Inc's reported EPS for the quarter
was a
loss of 27 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Sigilon Therapeutics Inc shares had fallen by 6.7% this
quarter and lost 82.9% so far this year.
    * The company reported a quarterly loss of $8.67 million.
    * Wall Street's median 12-month price target for Sigilon
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 02:25 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.42          -0.27          Beat
 Jun. 30 2022      -0.43          -0.44          Missed
 Mar. 31 2022      -0.33          -0.43          Missed
 Dec. 31 2021      -0.56          -0.55          Beat